2024-09-08 - Analysis Report
## Pfizer Inc. (PFE) Stock Analysis Report

**Company Overview:**  Pfizer is a multinational pharmaceutical corporation that develops and manufactures medicines and vaccines. 

**1. Performance vs. S&P 500 (VOO):**

* **Cumulative Return (PFE):** -27.44%
* **Cumulative Return (VOO):** 81.34%
* **Performance Difference:** -108.78%
* **Relative Divergence:** 7.37% 

PFE has significantly underperformed the S&P 500 over the period analyzed.  While VOO has delivered positive returns, PFE has seen a substantial decline. The relative divergence suggests that PFE's underperformance sits at the 7.37 percentile of its historical range against the S&P 500.

**2. Recent Price Movement:**

* **Closing Price:** $28.56
* **5-day Moving Average:** $28.55
* **20-day Moving Average:** $28.71
* **60-day Moving Average:** $28.81

PFE's recent price movement suggests a relatively stable period with the stock hovering slightly below its 5, 20, and 60-day moving averages.  

**3. Technical Indicators Analysis:**

* **RSI:** 55.04
* **PPO:** -0.11
* **Delta_Previous_Relative_Divergence:** -2.5 (Short-term decline)
* **Expected Return:** 0.0%

The RSI indicates that PFE is currently in the neutral territory. The PPO is slightly negative, suggesting potential downward pressure. The recent decline in relative divergence points towards a short-term downward trend. The expected return of 0.0% implies limited potential for significant gains in the next five years.

**4. Recent Earnings and Outlook:**

| Date | EPS | Expected EPS |
|---|---|---|
| 2024-07-30 | 0.6 | 0.458 |
| 2024-05-01 | 0.82 | 0.516 |
| 2024-01-30 | 0.1 | -0.19 |
| 2023-10-31 | -0.17 | -0.32 |
| 2023-08-01 | 0.67 | 0.56 |

Pfizer's most recent earnings report for the quarter ending July 30, 2024, showed an EPS of $0.6, exceeding the analyst expectation of $0.458. However, it is important to note that the company has shown volatility in earnings over the past few quarters.  Future performance will likely be driven by the success of new drug launches and the continued impact of COVID-19-related products.

**5. Summary Analysis:**

Pfizer's performance has been significantly lagging behind the broader market, marked by a negative cumulative return. Technical indicators suggest a potential for short-term downward pressure, with a limited expected return over the next five years. Recent earnings have shown some improvement, exceeding analyst expectations. However, the company faces challenges in maintaining consistent profitability and future success will depend on its ability to navigate market shifts and successfully introduce new products.

**6. Conclusion:**

Overall, PFE presents a mixed picture. While recent earnings have been positive, its underperformance against the market and technical indicators suggest caution. Investors should closely monitor the company's future performance, particularly its ability to sustain growth in new product lines and address challenges posed by a changing pharmaceutical landscape. 
